Biodexa Pharmaceuticals Files 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Feb 24, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, regulatory-update
TL;DR
Biodexa Pharma (fka Midatech) filed a 6-K, confirming 20-F annual report filings.
AI Summary
Biodexa Pharmaceuticals Plc filed a Form 6-K on February 24, 2025, reporting for the month of February 2025. The company, formerly known as Midatech Pharma Plc, is incorporated in the UK and has its principal executive office in Cardiff. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulatory bodies, confirming the company's reporting status and structure.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial information or significant operational updates.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Filer of the report
- Midatech Pharma Plc (company) — Former name of the registrant
- February 24, 2025 (date) — Filing date
- Form 6-K (document) — Type of SEC filing
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information for the month of February 2025 and to confirm that Biodexa Pharmaceuticals Plc files annual reports under Form 20-F.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on February 24, 2025.
What was Biodexa Pharmaceuticals Plc formerly known as?
Biodexa Pharmaceuticals Plc was formerly known as Midatech Pharma Plc.
Where is Biodexa Pharmaceuticals Plc's principal executive office located?
Biodexa Pharmaceuticals Plc's principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does this filing contain new financial information or operational updates?
No, this filing is a routine report and the information furnished is not deemed 'filed' for the purposes of Section 18 of the Exchange Act, nor does it appear to contain new material financial information or significant operational updates.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 24, 2025 regarding Biodexa Pharmaceuticals Plc (BDRX).